Minerva Neurosciences (NASDAQ:NERV) Price Target Cut to $5.00

Minerva Neurosciences (NASDAQ:NERV) had its price objective decreased by HC Wainwright from $7.00 to $5.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 67.22% from the stock’s previous close.

Separately, StockNews.com started coverage on shares of Minerva Neurosciences in a research report on Tuesday. They issued a “sell” rating for the company.

Minerva Neurosciences Trading Up 1.7 %

Shares of NERV stock traded up $0.05 on Wednesday, reaching $2.99. 10,985 shares of the stock were exchanged, compared to its average volume of 69,683. The company has a market capitalization of $20.91 million, a price-to-earnings ratio of -0.64 and a beta of 0.15. The business’s 50 day moving average price is $3.15 and its 200 day moving average price is $3.92. Minerva Neurosciences has a twelve month low of $2.26 and a twelve month high of $13.49.

Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.12). Equities research analysts forecast that Minerva Neurosciences will post -1.89 earnings per share for the current year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.